Current Report Filing (8-k)
September 12 2017 - 03:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
September 12, 2017
OWC
P
harmaceutical
R
esearch
C
orp.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware
|
98-0573566
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
30 Shacham Street. P.O.B.
8324 Petach Tikva, Israel
|
4918103
|
(Address of Principal Executive Offices)
|
(ZIP Code)
|
Registrant's
Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On September 11, 2017, OWC Pharmaceutical Research Corp. (the
"Registrant") learned of a "news article" that posted on a website: www.WallStreetWhispers.blogspot.co, a copy of which is attached as Exhibit 99.1
hereto. https://wallstreetwhispers.blogspot.co.il/2017/09/pfizer-pfe-and-owc-pharmaceutical-owcp.html?m=1]
The Registrant is not the source of this "news article" nor
does the Registrant know who is the author of the posted "news article." The
Registrant cautions investors to rely solely on the Registrant's public filings
with the United States Securities and Exchange Commission, including its reports
filed with the SEC on Form 8-K, and press releases published directly by the
Registrant.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to
this report on Form 8-K or incorporated by reference herein. Any document incorporated by
reference is identified by a parenthetical reference to the SEC filing that included such
document.
Exhibit
No.
|
Description
|
99.1
|
Blog Posting dated September 11, 2017, filed herewith.
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
OWC Pharmaceutical
Research Corp.
|
|
|
|
|
|
By:
/s/ Mordechai
Bignitz
|
|
|
Name: Mordechai Bignitz
|
|
|
Title: Chief Executive
Officer
|
|
Date: September 12, 2017
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Feb 2024 to Mar 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about OWC Pharmaceuticals Research Corporation (CE) (OTCMarkets): 0 recent articles
More Owc Pharmaceutical Research Corp. News Articles